AUG 04, 2020 4:27 PM PDT

Erectile Dysfunction Drug Cures Critical COVID-19 Patients

WRITTEN BY: Annie Lennon

Critically ill patients who received COVID-19 drug candidate aviptadil (RLF-100) were able to make a rapid recovery from respiratory failure from COVID-19, according to pharmaceutical companies NeuroRX and Relief Therapeutics.

Typically used alongside phentolamine to treat erectile dysfunction, the first report on the drug's success comes from doctors in Houston Methodist Hospital. 

Although these early results are yet to be released, the report highlights the case of a 54-year-old man who contracted COVID-19 while receiving treatment for rejection of a double lung transplant. Within four days of treatment with RLF-100, he reportedly came off the ventilator. The companies say that similar results also came for 15 other patients treated under emergency use. 

More than this, the report supposedly highlights the rapid clearance of classic pneumonitis findings on x-rays, improved blood oxygen, and a 50% or greater average reduction in laboratory markers for inflammation by COVID-19. 

An independent research team at the Oswaldo Cruz Foundation in Rio de Janeiro, Brazil, also showed that the drug candidate was able to prevent SARS coronavirus replication in human lung cells and monocytes in Petri dishes. 

Although promising results, due to the relatively small sample size, and other limitations, Jonathon Javitt, NeuroRx CEO and Chairman remains cautious. 

"If you ask me whether this is the cure to COVID, my answer is that I don't know, but it shows promise, and I hope so," says Javitt. "Of course, this is a small number [refering to patient data so far], and of course, testing that includes patients given placebos is needed."

Last week, the US Food and Drug Administration granted the drug an Expanded Access Protocol to treat respiratory distress from COVID-19. This means that the drug can be administered on an emergency basis to patients who are too ill to join a clinical trial and pregnant women. Meanwhile, Phase II/III trials involving 70 people are still ongoing. 

 

Sources: Clinical Trial ArenaTimes of Israel

About the Author
  • Science writer with keen interests in technology and behavioral biology. Her current focus is on the interplay between these fields to create meaningful interactions, applications and environments.
You May Also Like
JUL 15, 2020
Cancer
Traditional Medicine Reveals a New Anti-Cancer Drug
JUL 15, 2020
Traditional Medicine Reveals a New Anti-Cancer Drug
The art of traditional eastern medicine dates back thousands of years. It uses many unproven remedies, and many consider ...
JUL 20, 2020
Cancer
Fighting Cancer with Black Pepper
JUL 20, 2020
Fighting Cancer with Black Pepper
In the never-ending search for the next treatment or cure, many researchers turn towards nature. The study of black pepp ...
JUL 19, 2020
Cannabis Sciences
Cannabis May Relieve Pain from Sickle Cell Disease
JUL 19, 2020
Cannabis May Relieve Pain from Sickle Cell Disease
Due to the rise in opioid-associated deaths, physicians and researchers are on the constant lookout for new, healthier o ...
JUL 19, 2020
Drug Discovery & Development
Nanodrug for Treating Invasive Breast Cancer
JUL 19, 2020
Nanodrug for Treating Invasive Breast Cancer
Scientists at the University of Arkansas created a nano-drug that may eradicate triple-negative breast cancer cells. Fin ...
AUG 04, 2020
Neuroscience
Transcranial Stimulation Disrupts Fearful Memories
AUG 04, 2020
Transcranial Stimulation Disrupts Fearful Memories
Disrupting negative memory formation has been a challenge for years- involving treatments ranging from psychotherapy to ...
AUG 11, 2020
Drug Discovery & Development
Engineering Drug-Producing Bacteria
AUG 11, 2020
Engineering Drug-Producing Bacteria
Researchers at Rice University worked to program a bacterium, Escherichia coli, to produce a synthetic "noncanonica ...
Loading Comments...